Rize Oncology (XCNQ:RIZE) Valuation Rank

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Rize Oncology Valuation Rank Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.

Executives

William James Garner

10% Security Holder, Director